The SHAMROCK study is another trial of neoadjuvant T-DXd in early stage HER2-positive breast cancer, which incorporates therapy escalation and de-escalation strategies using an on-treatment biopsy and imaging (92). Here, ERBB2 is linked to breast carcinoma.